Open Access Article

Putting Evidence Into Practice®: Evidence-Based Interventions to Prevent and Manage Anorexia

Lynn A. Adams

Nancy Shepard

Rose Ann Caruso

Martha J. Norling

Heather Belansky

Regina S. Cunningham

evidence-based practice, anorexia
CJON 2009, 13(1), 95-102. DOI: 10.1188/09.CJON.95-102

Anorexia is defined as an involuntary loss of appetite.Approximately 50% of newly diagnosed patients with cancer experience the symptom, which often is accompanied by weight loss and most typically associated with advanced disease.Anorexia significantly affects the clinical course of cancer; it can lead to the development or exacerbation of disease- or treatment-related symptoms, decreased functional status, and diminished quality of life.As part of the Oncology Nursing Society's Putting Evidence Into Practice® initiative, a team of oncology nurses examined and evaluated published research literature for the purpose of developing an evidence-based practice resource focused on the management of cancer-related anorexia.Even though anorexia is common among newly diagnosed patients and those with advanced disease, interventions to prevent, treat, and manage the symptom are limited.The evidence revealed that only two pharmacologic interventions, corticosteroids and progestins, can be recommended for use in clinical practice, and dietary counseling was identified as likely to be effective.This article summarizes selected empirical literature on interventions used to prevent and manage anorexia in patients with cancer.Familiarity with the literature will assist oncology nurses in proactively identifying and effectively managing patients experiencing this distressing symptom.

Jump to a section


    Adams, L., Cunningham, R., Shepard, N., Caruso, R.A., Norling, M.J., & Belansky, H. (2008). Oncology Nursing Society Putting Evidence Into Practice®: Anorexia. Retrieved January 16, 2008, from
    Berenstein, E.G., & Ortiz, Z. (2005). Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews, 2(2), CD004310.
    Brown, J.K. (2002). A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia. Oncology Nursing Forum, 29(3), 517-530.
    Bruera, E., Neumann, C.M., Pituskin, E., Calder, K., Ball, G., & Hanson, J. (1999). Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Annals of Oncology, 10(7), 857-859.
    Bruera, E., Strasser, F., Palmer, J.L., Willey, J., Calder, K., Amyotte, G., et al. (2003). Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: A double-blind, placebo-controlled study. Journal of Clinical Oncology, 21(1), 129-134.
    Cangiano, C., Laviano, A., Meguid, M.M., Mulieri, M., Conversano, L., Preziosa, I., et al. (1996). Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. Journal of the National Cancer Institute, 88(8), 550-552.
    Celegene Corporation. (2007). Thalomid®. Retrieved July 31, 2008, from
    Daneryd, P., Svanberg, E., Korner, U., Lindholm, E., Sandstrom, R., Brevinge, H., et al. (1998). Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study. Cancer Research, 58(23), 5374-5379.
    Desport, J.C., Gory-Delabaere, G., Blanc-Vincent, M.P., Bachmann, P., Beal, J., Benamouzig, R., et al. (2003). Standards, options and recommendations for the use of appetite stimulants in oncology (2000). British Journal of Cancer, 89(Suppl. 1), S98-S100.
    DeWys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al. (1980). Prognostic effect of weight loss prior to chemotherapy in cancer patients.Eastern Cooperative Oncology Group. American Journal of Medicine, 69(4), 491-497.
    Fearon, K.C., Barber, M.D., Moses, A.G., Ahmedzai, S.H., Taylor, G.S., Tisdale, M.J., & Murray, G.D. (2006). Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. Journal of Clinical Oncology, 24(21), 3401-3407.
    Gagnon, B., & Bruera, E. (1998). A review of the drug treatment of cachexia associated with cancer. Drugs, 55(5), 675-688.
    Goldberg, R.M., Loprinzi, C.L., Mailliard, J.A., O'Fallon, J.R., Krook, J.E., Ghosh, C., et al. (1995). Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 13(11), 2856-2859.
    Gordon, J.N., Trebble, T.M., Ellis, R.D., Duncan, H.D., Johns, T., & Goggin, P.M. (2005). Thalidomide in the treatment of cancer cachexia: A randomized placebo controlled trial. Gut, 54(4), 540-545.
    Inoue, A., Yamada, Y., Matsumura, Y., Shimada, Y., Muro, K., Gotoh, M., et al. (2003). Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Supportive Care in Cancer, 11(8), 528-532.
    Jatoi, A., Dakhil, S.R., Nguyen, P.L., Sloan, J.A., Kugler, J.W., Rowland, K.M., Jr., et al. (2007). A placebo-controlled double blind trial of etanercept for cancer anorexia/weight loss syndrome. Cancer, 110(6), 1396-1403.
    Jatoi, A., Rowland, K., Loprinzi, C.L., Sloan, J.A., Dakhil, S.R., MacDonald, N., et al. (2004). An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. Journal of Clinical Oncology, 22(12), 2469-2476.
    Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan.J.A., Dakhil, S.R., Mailliard, J.A., et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. Journal of Clinical Oncology, 20(2), 567-573.
    Kardinal, C.G., Loprinzi, C.L., Schaid, D.J., Hass, A.C., Dose, A.M., Athmann, L.M., et al. (1990). A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer, 65(12), 2657-2662.
    Lai, J., Cella, D., Peterman, A., Barocas, J., & Goldman, S. (2005). Anorexia/cachexia-related quality of life for children with cancer. Cancer, 104(7), 1531-1539.
    Lambert, D.M. & Fowler, C.J. (2005). The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications. Journal of Medicinal Chemistry, 48(16), 5059-5087.
    Laviano, A., Meguid, M.M., & Fanelli, F.R. (2006). Anorexia.In G.Montovani, S.D.Anker., A.Inui, J.E.Morley, F.Rossi Fanelli, D.Scevols, et al. (Eds.), Cachexia and wasting: A modern approach (pp. 139-148). Springer: Milan.
    Laviano, A., & Rossi-Fanelli, F. (2003). Pathogenesis of cancer anorexia: Still doubts after all these years? Nutrition, 19(1), 67-68.
    Lissoni, P., Chilelli, M., Villa, S., Cerizza, L., & Tancini, G. (2003). Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. Journal of Pineal Research, 35(1), 12-15.
    Lissoni, P., Paolorossi, F., Tancini, G., Barni, S., Ardizzoia, A., Brivio, F., et al. (1996). Is there a role for melatonin in the treatment of neoplastic cachexia? European Journal of Cancer, 32(8), 1340-1343.
    Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Mailliard, J.A., Krook, J.E., Wilwerding, M.B., et al. (1999). Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology, 17(10), 3299-3306.
    Lundholm, K., Daneryd, P., Bosaeus, I., Koerner, U., & Lindholm, E. (2004). Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignancy disease: Effects on survival, metabolism, and function. Cancer, 100(9), 1967-1977.
    Maltoni, M., Nanni, O., Scarpi, E., Rossi, D., Serra, P., & Amadori, D. (2001). High-dose progestins for the treatment of cancer anorexiacachexia syndrome: A systematic review of randomised clinical trials. Annals of Oncology, 12(3), 289-300.
    Moertel, C.G., Schutt, A.J., Reitemeier, R.J., & Hahn, R.G. (1974). Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer, 33(6), 1607-1609.
    Neary, N.M., Small, C.J., Wren, A.M., Lee, J.L., Druce, M.R., Palmieri, C., et al. (2004). Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 89(6), 2832-2836.
    Pawlowski, G.J. (1975). Cyproheptadine: Weight-gain and appetite stimulation in essential anorexic adults. Current Therapeutic Research, Clinical and Experimental, 18(5), 673-678.
    Priovano, M., Maltoni, M., Nanni, O., Marinari, M., Indelli, M., Zaninetta, G., et al. (1999). A new palliative score: A first step for the staging of terminally ill cancer patients.Italian Multicenter and Study Group on Palliative Care. Journal of Pain and Symptom Management, 17(4), 231-239.
    Ravasco, P., Monteiro-Grillo, I., Vidal, P.M., & Camilo, P.E. (2005). Dietary counseling improves patient outcomes: A prospective, randomized, controlled trial, in colorectal cancer patients undergoing radiotherapy. Journal of Clinical Oncology, 23(7), 1431-1438.
    Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., et al. (2006). Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology, 24(21) 3394-4000.
    Strasser, F., Lutz, T.A., Maeder, M.T., Thuerlimann, B., Bueche, D., Tschop, M., et al. (2008). Safety, tolerability, and pharmacokinetics of intravenous ghrelin for cancer related anorexia/cachexia: a randomized, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer, 98(2), 300-308.
    Tipton, J.M., McDaniel, R.W., Barbour, L., Johnston, M.P., Kayne, M., LeRoy, P., et al. (2007). Putting Evidence Into Practice®: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 11(1), 69-78
    Tisdale, M.J. (2003). Pathogenesis of cancer cachexia. Supportive Oncology, 1(3), 159-168.
    Willox, J.C., Corr, J., Shaw, J., Richardson, M., Calman, K.C., & Drennan, M. (1984). Prednisolone as an appetite stimulant in patients with cancer. BMJ, 288(6410), 27.
    Yavuzsen, T., Davis, M.P., Walsh, D., Legrand, S., & Lagman, R. (2005). Systematic review of the treatment of cancer-associated anorexia and weight loss. Journal of Clinical Oncology, 23(33), 8500-8511.